GAMMARETROVIRUS ASSOCIATED WITH CANCER patent

[leelaplay]

[if:I wonder what the status of this patent is:]

(WO/2006/110589) GAMMARETROVIRUS ASSOCIATED WITH CANCER

Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2006/110589 International Application No.: PCT/US2006/013167
Publication Date: 19.10.2006 International Filing Date: 07.04.2006
IPC: C12N 7/00 (2006.01), A61K 39/21 (2006.01), C07K 14/15 (2006.01), C12N 15/11 (2006.01), C12N 15/63 (2006.01), C12N 5/10 (2006.01), C12N 7/02 (2006.01), C12Q 1/68 (2006.01), G01N 33/50 (2006.01), G01N 33/569 (2006.01)

Applicants: THE CLEVELAND CLINIC FOUNDATION [US/US]; CCF INNOVATIONS/D20, 9500 Euclid Avenue, Cleveland, Ohio 44195 (US) (All Except US).
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 111 Franklin Street, 12th Floor, Oakland, California 94607 (US) (All Except US).
SILVERMAN, Robert [US/US]; (US) (US Only).
KLEIN, Eric, A. [US/US]; (US) (US Only).
DERISI, Joseph [US/US]; (US) (US Only).
GANEM, Don [US/US]; (US) (US Only).
CASEY, Graham [US/US]; (US) (US Only).

Inventors: SILVERMAN, Robert; (US).
KLEIN, Eric, A.; (US).
DERISI, Joseph; (US).
GANEM, Don; (US).
CASEY, Graham; (US).

Agent: COLLINS, Anne, J. et al.; HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 Virginia Road, P.O. Box 9133, Concord, Massachusetts 01742-9133 (US) .
Priority Data:
60/669,473 07.04.2005 US
60/751,809 19.12.2005 US

Title: GAMMARETROVIRUS ASSOCIATED WITH CANCER
Abstract: The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.

Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)

 

[Otis]

Good question. It appears the patent was filed in the US in '05.

While this is an intellectual property claim (albeit an unbelievably complex and detailed one) and not a scientific paper this is the first statement of the presence of, or increased risk for cancer associated with the detection of XMRV that I've seen - and from Dr. Silveman nonetheless. Perhaps this is typical for IP statements I've never read one for a medical application such as this.

Here's one snippet from the (lengthy) description from the WIPO site.

The present invention is also directed to methods of detecting XMRV. In one embodiment, detection of XRMV in an individual indicates that the individual has cancer or at risk of developing cancer (e.g., prostate cancer). The method can comprise detecting the XMRV in the individual by detecting a nucleic acid sequence that encodes all or a portion of the XMRV (e.g., a nucleic acid sequence having at least 94% identity to SEQ ID NO: 1 or a complement thereof). Alternatively, the method can comprise detecting the XMRV in the individual by detecting a polypeptide encoded by the XMRV (e.g., a gag polypeptide, a pol polypeptide, an env polypeptide and combinations thereof).

Interesting stuff.

Otis